Gen Digital Inc. Stock Falls 4.0%, Underperforms Peers
Dow Jones2026/09/18 20:34This article was automatically generated by Dow Jones using technology from Automated Insights.
Shares of Gen Digital Inc. slid 4.0% to $29.01 on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index rising 0.2% to 7,650.50 and the Dow Jones Industrial Average falling 0.2% to 51,682.64.
This was the stock's fourth consecutive day of losses.
Gen Digital Inc. closed 8.3% short of its 52-week high of $31.65, which the company achieved on September 3rd.
The stock underperformed when compared to some of its peers, as Microsoft Corp. fell 0.8% to $493.78, Fortinet Inc. fell 1.6% to $169.84, and Equifax Inc. fell 1.43% to $158.87.
Trading volume totaled 18.9 million, compared to the 50-day average of 5.0 million.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
September 18, 2026 16:34 ET (20:34 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
WTI crude oil futures prices fall by more than 1%
Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment
According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.
GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions
Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.
BUZZ-3M India shares fall to 19-month low due to quarterly profit decline
Crypto prices
More
